Breast Cancer Research and Treatment

, Volume 121, Issue 3, pp 679–683

Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years

  • Mats Lambe
  • Annette Wigertz
  • Marit Holmqvist
  • Jan Adolfsson
  • Carola Bardage
  • Tommy Fornander
  • Per Karlsson
  • Viveca Odlind
  • Ingemar Persson
  • Johan Ahlgren
  • Leif Bergkvist
Epidemiology

Abstract

Studies from Western countries have found evidence of a recent decline in breast cancer incidence rates in postmenopausal women, findings which have been hypothesized to reflect a reduced use of hormonal replacement therapy (HRT). We examined breast cancer incidence trends in Sweden between 1997 and 2007, a period characterized by a drop in the use of HRT. Incidence trends were assessed using data from three population-based Regional Clinical Registries on breast cancer covering 2/3 of the Swedish population. Information on HRT sales was obtained from national pharmacy data. The prevalence of HRT use in age group 50–59 years decreased from a peak of 36% in 1999 to 27% in 2002 and further to 9% in 2007. Incidence rates of breast cancer in women 50 years and older increased between 1997 and 2003. A significant decrease in incidence between 2003 and 2007 was confined to women 50–59 years of age, the group in which the prevalence of HRT use has been highest and the decrease in use most pronounced. As opposed to the immediate effects reported from the United States and other regions, there was a time lag between the drop in HRT use and clear reductions in breast cancer incidence. This may reflect between country differences with regard to types of HRT used, and the rate, magnitude and pattern of change in use. The present findings give further support to the notion that HRT use is a driver of breast cancer incidence trends on the population level.

Keywords

Breast cancer Incidence Trends Hormone replacement therapy Sweden 

References

  1. 1.
    Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670–1674CrossRefPubMedGoogle Scholar
  2. 2.
    Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ (2006) Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 24:e49–e50CrossRefPubMedGoogle Scholar
  3. 3.
    Glass AG, Lacey JV Jr, Carreon JD, Hoover RN (2007) Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99:1152–1161CrossRefPubMedGoogle Scholar
  4. 4.
    Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9:R28CrossRefPubMedGoogle Scholar
  5. 5.
    Keegan TH, Chang ET, John EM, Horn-Ross PL, Wrensch MR, Glaser SL, Clarke CA (2007) Recent changes in breast cancer incidence and risk factor prevalence in San Francisco Bay area and California women: 1988 to 2004. Breast Cancer Res 9:R62CrossRefPubMedGoogle Scholar
  6. 6.
    Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA (2007) Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 99:1335–1339CrossRefPubMedGoogle Scholar
  7. 7.
    Robbins AS, Clarke CA (2007) Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 25:3437–3439CrossRefPubMedGoogle Scholar
  8. 8.
    Canfell K, Banks E, Moa AM, Beral V (2008) Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 188:641–644PubMedGoogle Scholar
  9. 9.
    Hemminki E, Kyyronen P, Pukkala E (2008) Postmenopausal hormone drugs and breast and colon cancer: nordic countries 1995–2005. Maturitas 61:299–304CrossRefPubMedGoogle Scholar
  10. 10.
    Katalinic A, Rawal R (2008) Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107:427–430CrossRefPubMedGoogle Scholar
  11. 11.
    Bouchardy C, Usel M, Verkooijen HM, Fioretta G, Benhamou S, Neyroud-Caspar I, Schaffar R, Vlastos G, Wespi Y, Schäfer P, Rapiti E (2009) Changing pattern of age-specific breast cancer incidence in the Swiss canton of Geneva. Breast Cancer Res Treat. doi:10.1007/s10549-009-0478-y
  12. 12.
    Parkin DM (2009) Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer 45:1649–1653CrossRefPubMedGoogle Scholar
  13. 13.
    Seradour B, Allemand H, Weill A, Ricordeau P (2009) Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. Bull Cancer 96:E1–E6PubMedGoogle Scholar
  14. 14.
    Vankrunkelsven P, Kellen E, Lousbergh D, Cloes E, Op de Beeck L, Faes C, Bruckers L, Mertens R, Coebergh JW, Van Leeuwen FE, Buntinx F (2009) Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat 118:425–432Google Scholar
  15. 15.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefPubMedGoogle Scholar
  16. 16.
    Krieger N (2008) Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections. Int J Epidemiol 37:627–637CrossRefPubMedGoogle Scholar
  17. 17.
    Li CI, Daling JR (2007) Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16:2773–2780CrossRefPubMedGoogle Scholar
  18. 18.
    Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Lancet 350:1047–1059CrossRefGoogle Scholar
  19. 19.
    Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360:573–587CrossRefPubMedGoogle Scholar
  20. 20.
    Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC (2009) The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999–2004. Cancer Epidemiol Biomarkers Prev 18:1763–1769Google Scholar
  21. 21.
    Olsson S, Andersson I, Karlberg I, Bjurstam N, Frodis E, Hakansson S (2000) Implementation of service screening with mammography in Sweden: from pilot study to nationwide programme. J Med Screen 7:14–18CrossRefPubMedGoogle Scholar
  22. 22.
    Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427CrossRefPubMedGoogle Scholar
  23. 23.
    Olsson HL, Ingvar C, Bladstrom A (2003) Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 97:1387–1392CrossRefPubMedGoogle Scholar
  24. 24.
    Warren MP (2004) A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obstet Gynecol 190:1141–1167CrossRefPubMedGoogle Scholar
  25. 25.
    Hoffmann M, Hammar M, Kjellgren KI, Lindh-Astrand L, Brynhildsen J (2005) Changes in women’s attitudes towards and use of hormone therapy after HERS and WHI. Maturitas 52:11–17CrossRefPubMedGoogle Scholar
  26. 26.
    Thunell L, Stadberg E, Milsom I, Mattsson LA (2005) Changes in attitudes, knowledge and hormone replacement therapy use: a comparative study in two random samples with 6-year interval. Acta Obstet Gynecol Scand 84:395–401PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Mats Lambe
    • 1
    • 2
  • Annette Wigertz
    • 2
    • 3
  • Marit Holmqvist
    • 2
  • Jan Adolfsson
    • 3
  • Carola Bardage
    • 4
  • Tommy Fornander
    • 5
  • Per Karlsson
    • 6
  • Viveca Odlind
    • 4
  • Ingemar Persson
    • 4
  • Johan Ahlgren
    • 7
  • Leif Bergkvist
    • 8
  1. 1.Department of Medical Epidemiology and BiostatisticsKarolinska InstitutetStockholmSweden
  2. 2.Regional Oncologic CentreUppsalaSweden
  3. 3.Oncologic Centre Stockholm and GotlandKarolinska University HospitalStockholmSweden
  4. 4.Medical Product AgencyUppsalaSweden
  5. 5.Department of Oncology and PathologyKarolinska InstitutetStockholmSweden
  6. 6.Department of OncologySahlgrenska University HospitalGothenburgSweden
  7. 7.Department of Oncology and Centre for Research and DevelopmentUppsala University, Gävle HospitalGävleSweden
  8. 8.Department of Surgery and Centre for Clinical ResearchUppsala University, Central HospitalVästeråsSweden

Personalised recommendations